Myelodysplastic syndrome overview.23111DEFANGED-ppt 3.57.51 PM

Myelodysplastic syndrome overview.23111DEFANGED-ppt 3.57.51 PM

Info iconThis preview shows pages 1–8. Sign up to view the full content.

View Full Document Right Arrow Icon
Myelodysplastic syndrome overview Razelle Kurzrock Seminars in Haematology, Vol 39, No 3, Suppl 2 (July) 2002, pp 18-25
Background image of page 1

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
Myelodysplastic syndrome (MDS) It is a term for a heterogeneous collection of haemopoietic stem cell disorders affecting older adults. There is underlying ineffectiveness of haemopoiesis that results in dysplasia of bone marrow precursors and peripheral cytopenias.
Background image of page 2
Moderate anaemia is the most common clinical problem in MDS patients, but complete myeloid bone marrow failure also occurs leading to death from bleeding or infection. Approximately half of the patients transform to AML .
Background image of page 3

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
Prognosis depends on the individual’s risk factors, with median survival ranging from 5.7 years in lower-risk group to 1.2 years or less in those with higher-risk MDS. MDS is extremely difficult to treat. Most cases are resistant to current therapies, and the most potent anti-MDS treatments (transplantation and dose intensive chemotherapy) are often too toxic for the majority of patients.
Background image of page 4
MDS background Pathobiology The cardinal features of MDS are Increased marrow proliferation Failure of stem cells to differentiate And increased marrow apoptosis. The disease is of clonal origin Chromosomal abnormalities are detectable in 30-70% of patients. The no. of chromosomal abn. may correlate with the risk of progression to AML.
Background image of page 5

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
Background image of page 6
FAB classification In 1982 The FAB group classified MDS according to Morphology and the % of myeloblasts in the BM and PB. These included
Background image of page 7

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
Image of page 8
This is the end of the preview. Sign up to access the rest of the document.

Page1 / 25

Myelodysplastic syndrome overview.23111DEFANGED-ppt 3.57.51 PM

This preview shows document pages 1 - 8. Sign up to view the full document.

View Full Document Right Arrow Icon
Ask a homework question - tutors are online